読み込み中
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
終値時点
$11.29
+$0.08 · +0.71%
時間外
$11.29
$0.00 · 0.00%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日中レンジ
現在 $11.29
52週レンジ
現在 $11.29
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
54
適正価値
センチメント
41
まちまち
リスク
53
やや高いリスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
日中レンジ
現在 $11.29
52週レンジ
現在 $11.29
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（AUD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 12.05億 AUD | 7.83億 AUD | 5.03億 AUD | 1.6億 AUD | 759.6万 AUD |
| 売上原価 | 5.65億 AUD | 2.74億 AUD | 1.88億 AUD | 6517万 AUD | 3868.22万 AUD |
| 粗利益 | 6.4億 AUD | 5.1億 AUD | 3.14億 AUD | 9492.6万 AUD | 504.8万 AUD |
| 研究開発 | 2.57億 AUD | 1.21億 AUD | 1.29億 AUD | 5785.7万 AUD | 3413.5万 AUD |
| 販売・一般管理 | 3.57億 AUD | 2.07億 AUD | 1.34億 AUD | 8709.8万 AUD | 4698.6万 AUD |
| 営業費用 | 6.14億 AUD | 4.28億 AUD | 2.63億 AUD | 1.87億 AUD | 5330.26万 AUD |
| 受取利息 | 873.71万 AUD | 1086.2万 AUD | 67.1万 AUD | 1000 AUD | — |
| 支払利息 | 5506.34万 AUD | 2146.4万 AUD | 894.3万 AUD | 40.6万 AUD | 19.57万 AUD |
| 減価償却費と償却費 | 3266.58万 AUD | 802.68万 AUD | 674.3万 AUD | 537.9万 AUD | 517.4万 AUD |
| 営業利益 | 2664.17万 AUD | 8213万 AUD | 1584万 AUD | −9193万 AUD | −8124.7万 AUD |
| 純利益 | −1068.52万 AUD | 4991.9万 AUD | 521.1万 AUD | −1.04億 AUD | −8051万 AUD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$18.00
上昇余地（59.43%）この株式へのエクスポージャーを報告している上場投資信託です。
Schwab International Equity ETFSCHF1847.44万0.03%674.08億 USD0.03%$27.13-0.51%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1035.1万0.03%404.62億 USD0.03%$49.69-0.58%
Schwab Fundamental International Small Company Index ETFFNDC517.53万0.17%30.73億 USD0.39%$49.50-0.48%
John Hancock Investments - Multifactor Developed International ETFJHMD94.74万0.10%9.65億 USD0.39%$43.96-0.29%
State Street SPDR Portfolio Europe ETFSPEU35.14万0.05%6.89億 USD0.07%$53.02-0.21%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA24.9万0.03%10.17億 USD0.30%$97.45-0.24%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX21.31万0.04%4.88億 USD0.20%$53.12-0.38%
ActivePassive International Equity ETFAPIE13.14万0.01%11.41億 USD0.45%$38.40-0.41%Schwab International Equity ETFSCHFState Street SPDR Portfolio Developed World ex-US ETFSPDWSchwab Fundamental International Small Company Index ETFFNDCJohn Hancock Investments - Multifactor Developed International ETFJHMDState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXActivePassive International Equity ETFAPIEAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
